Video consultations for cancer treatment recommendations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to enhance the effectiveness of video tumor boards for patients with malignant melanoma by facilitating expert consultations across multiple specialties. The initiative seeks to ensure that patients, regardless of their geographic location, can access specialized cancer care and benefit from collective expertise in oncology. By focusing on skin cancer as a starting point, the study will evaluate how telemedicine can improve treatment recommendations for complex cases. The study includes adult patients who meet specific criteria for presentation at cancer care centers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The study includes adult, external patients who, according to the certification requirements of the German Cancer Society, should be presented to the CCCs in a tumor board .

Inclusion criteria for patients:

* Minimum age 18 years
* Consent to participate in the study (signing of patient consent) should be presented in vTB+ according to the doctor, based on the disease/diagnosis, especially in the case of:

  * Malignant melanoma from stage IIB
  * Malignant melanoma and stage shift/recurrence o Extracutaneous melanoma o Cutaneous lymphoma from stage Ib o Problem cases with malignant, epithelial tumors (BCC, SCC) with interdisciplinary issues, e.g. complicated localization, extension/ infiltration (e.g. Ulcus rodens, Ulcus terebrans), metastasized tumors, immunosuppressed patients o all rare malignant skin tumors (including Merkel cell carcinoma, DFSP, MFH, leiomyosarcoma, S., Kaposi's sarcoma, angiosarcoma), regardless of stage o severe side effects from drug-based tumor therapy • is an external patient: An external patient is someone who receives tumor therapy exclusively or in co-treatment in the branch or in an external clinic (in distinction to patients without prior treatment for initial presentation at the CCC) . This also applies to patients who are only seen once at the vTB.

In this case, revenue/cost aspects and the DKG requirement are ignored. This means that so-called external patients can also be treated at the center, including initiation of therapy. The decisive factor is the presentation of the external patient (personal presentation of the external patients is not mandatory) and that external co-treaters are consistently informed and involved.

Inclusion criteria for external doctors:

* has a medical license
* has dermatological patients who are eligible to be presented in the vTB+

Exclusion Criteria:

Patients will be excluded from the study if they meet the following criteria:

* Linguistic or other limitations (such as dementia) that prevent independent consent to the privacy policy.
* No consent to participate in the study (patient consent) or withdrawal of consent during the course of the study In addition, external physicians will be excluded from the study if no joint cooperation agreement can be negotiated and signed.

Where it's running

• Nationales Centrum für Tumorerkrankungen Klinik u. Poliklinik für Dermatologie, Universitätsklinikum Dresden
  Dresden, Germany Recruiting
• Abteilung für Integrierte Onkologie - CIO Bonn, Universitätsklinikum Bonn
  Bonn, Germany Not yet recruiting
• Westdeutsches Tumorzentrum Münster, Universitätsklinikum Münster
  Münster, Germany Not yet recruiting

Study contacts

• Principal investigator: Philipp Lenz, MD — Westdeutsches Tumorzentrum Münster, Universitätsklinikum Münster
• Study coordinator: Philipp Lenz, MD
• Email: philipp.lenz@ukmuenster.de
• Phone: +49 251 83 43745

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Outpatient Cardiac Telerehabilitation for Ischemic Heart Disease

  This study tests whether an outpatient cardiac telerehabilitation program can be as safe and effective as conventional rehab for people with ischemic heart disease.

  Recruiting Lithuanian University of Health Sciences · Kulautuva · NCT07927829

• Tele-diabetes remote monitoring for kids with type 1 diabetes

  This study tests a tele-diabetes remote system that uses WhatsApp alerts to help children and teens manage their type 1 diabetes at home.

  Recruiting Sheba Medical Center · Ramat Gan · NCT07828106

• emPath platform pilot to link and keep adults with opioid use disorder in care in Durham

  This pilot tests a mobile app and telemedicine approach to help adults with opioid use disorder start and stay in MOUD through community outreach in Durham, NC.

  Recruiting Duke University · Durham, North Carolina · NCT07810322

• Social prescriptions and micro-learning to improve cancer care

  This study tests a multicomponent program using social prescriptions and short online learning to help cancer patients and their chosen support persons in Germany.

  Recruiting University of Regensburg · Augsburg, Bavaria and 7 other locations · NCT07788729

• Health Ahead: Comparing AI vs. Humans for Preventive Health Screening

  This study tests AI-assisted screening interpretation against human-only reads to see if automated screening can match or improve current practice for adults, especially in underserved areas.

  Recruiting Longevity Metrics, Inc. · Boulder, Colorado · NCT07669168

• TCC1727 combined with other cancer medicines for adults with advanced solid tumors

  This phase Ib/II trial tests TCC1727 given with benmelstobart, olaparib, or topotecan in adults with advanced solid tumors to find safe doses and see if the combinations help control tumors.

  Recruiting Phase 1/2 Beijing Tide Pharmaceutical Co., Ltd · Beijing, Beijing Municipality and 2 other locations · NCT07371663

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.